| Autor: |
Potocki PM; Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-008 Cracow, Poland., Wójcik P; Oncogene Diagnostics Sp. z o.o., 31-546 Cracow, Poland., Chmura Ł; Oncogene Diagnostics Sp. z o.o., 31-546 Cracow, Poland., Goc B; Student Research Group, Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-008 Cracow, Poland.; Radiotherapy Department, MSC National Research Institute of Oncology, 44-102 Gliwice, Poland., Fedewicz M; Student Research Group, Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-008 Cracow, Poland.; Józef Babiński Clinical Hospital, 30-393 Cracow, Poland., Bielańska Z; Student Research Group, Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-008 Cracow, Poland.; Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Regio Klinikum, 25337 Elmshorn, Germany., Swadźba J; Department of Laboratory Medicine, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, 30-705 Cracow, Poland., Konopka K; Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-008 Cracow, Poland., Kwinta Ł; Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-008 Cracow, Poland., Wysocki PJ; Oncology Department, Faculty of Medicine, Jagiellonian University Medical College, 31-008 Cracow, Poland. |
| Abstrakt: |
BRAF V600E and KRAS mutations that occur in colorectal cancer (CRC) define a subpopulation of patients with an inferior prognosis. Recently, the first BRAF V600E-targeting therapy has been approved and novel agents targeting KRAS G12C are being evaluated in CRC. A better understanding of the clinical characteristics of the populations defined by those mutations is needed. We created a retrospective database that collects clinical characteristics of patients with metastatic CRC evaluated for RAS and BRAF mutations in a single laboratory. A total of 7604 patients tested between October 2017 and December 2019 were included in the analysis. The prevalence of BRAF V600E was 6.77%. Female sex, primary in the right colon, high-grade, mucinous, signet cell, partially neuroendocrine histology, perineural and vascular invasion, and surgical tissue sample were factors associated with increased mutation rates. The prevalence of KRAS G12C was 3.11%. Cancer of primary origin in the left colon and in samples from brain metastases were associated with increased mutation rates. The high prevalence of the BRAF V600E mutation in cancers with a neuroendocrine component identifies a potential candidate population for BRAF inhibition. The association of KRAS G12C with the left part of the intestine and brain metastases of CRC are new findings and require further investigation. |
